Charles River Laboratories International (NYSE:CRL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Charles River Laboratories International (NYSE:CRL) from a hold rating to a buy rating in a research report sent to investors on Saturday.

A number of other equities research analysts also recently weighed in on the company. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Charles River Laboratories International in a research note on Thursday, January 22nd. Finally, Robert W. Baird set a $224.00 target price on shares of Charles River Laboratories International in a report on Friday, January 9th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $209.46.

Charles River Laboratories International Trading Down 1.9%

Shares of CRL stock opened at $185.53 on Friday. The firm has a fifty day moving average of $204.51 and a 200-day moving average of $180.02. The stock has a market cap of $9.13 billion, a price-to-earnings ratio of -118.93, a P/E/G ratio of 5.67 and a beta of 1.63. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently modified their holdings of CRL. Massachusetts Financial Services Co. MA bought a new position in Charles River Laboratories International in the 4th quarter worth approximately $176,478,000. Ameriprise Financial Inc. boosted its position in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after buying an additional 575,039 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 29.1% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after buying an additional 516,521 shares during the period. National Bank of Canada FI raised its position in shares of Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Charles River Laboratories International during the second quarter valued at $76,952,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.